Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Molecular Partners stock

Learn how to easily invest in Molecular Partners stock.

Molecular Partners AG ADR is a biotechnology business based in the US. Molecular Partners shares (MOLN) are listed on the NASDAQ and all prices are listed in US Dollars. Molecular Partners employs 164 staff and has a trailing 12-month revenue of around $189.9 million.

How to buy shares in Molecular Partners

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MOLN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Molecular Partners stock price (NASDAQ: MOLN)

Use our graph to track the performance of MOLN stocks over time.

Molecular Partners shares at a glance

Information last updated 2022-09-26.
Latest market close$6.15
52-week range$5.50 - $32.04
50-day moving average $6.32
200-day moving average $14.09
Wall St. target price$28.82
PE ratio 1.6639
Dividend yield $0 (0%)
Earnings per share (TTM) $3.62

Buy Molecular Partners shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 8 of 8
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Molecular Partners stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Partners price performance over time

Historical closes compared with the close of $6.1528 from 2022-09-27

1 week (2022-09-21) -1.08%
1 month (2022-08-26) -4.31%
3 months (2022-06-28) -18.83%
6 months (2022-03-28) -70.43%
1 year (2021-09-28) -68.09%
2 years (2020-09-28) -61.40%
3 years (2019-09-27) 16.7
5 years (2017-09-28) 25.65

Is Molecular Partners stock undervalued or overvalued?

Valuing Molecular Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Molecular Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Molecular Partners's P/E ratio

Molecular Partners's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Molecular Partners shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Molecular Partners's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Molecular Partners's EBITDA

    Molecular Partners's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $118.5 million.

    The EBITDA is a measure of a Molecular Partners's overall financial performance and is widely used to measure a its profitability.

    To put Molecular Partners's EBITDA into context you can compare it against that of similar companies.

    Molecular Partners financials

    Revenue TTM $189.9 million
    Operating margin TTM 61.95%
    Gross profit TTM $-45,964,000
    Return on assets TTM 29.04%
    Return on equity TTM 59.12%
    Profit margin 62.35%
    Book value $8.18
    Market capitalisation $198 million

    TTM: trailing 12 months

    Molecular Partners share dividends

    We're not expecting Molecular Partners to pay a dividend over the next 12 months.

    Molecular Partners share price volatility

    Over the last 12 months, Molecular Partners's shares have ranged in value from as little as $5.5 up to $32.04. A popular way to gauge a stock's volatility is its "beta".

    MOLN.US volatility(beta: 0.95)Avg. volatility(beta: 1.00)LowHigh

    Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Partners's is 0.9485. This would suggest that Molecular Partners's shares are less volatile than average (for this exchange).

    To put Molecular Partners's beta into context you can compare it against those of similar companies.

    Molecular Partners overview

    Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc. ; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators.

    Frequently asked questions

    What percentage of Molecular Partners is owned by institutions?
    Currently 3.065% of Molecular Partners shares are held by institutions.
    How many people work for Molecular Partners?
    Latest data suggests 164 work at Molecular Partners.
    When does the fiscal year end for Molecular Partners?
    Molecular Partners's fiscal year ends in December.
    Where is Molecular Partners based?
    Molecular Partners's address is: Wagistrasse 14, Schlieren, Switzerland, 8952
    What is Molecular Partners's ISIN number?
    Molecular Partners's international securities identification number is: US60853G1067

    More guides on Finder

    Ask an Expert

    You are about to post a question on finder.com:

    • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
    • finder.com is a financial comparison and information service, not a bank or product provider
    • We cannot provide you with personal advice or recommendations
    • Your answer might already be waiting – check previous questions below to see if yours has already been asked

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site